Publication: Immune response to influenza vaccination in ESRD patients undergoing hemodialysis vs. Hemodiafiltration
Issued Date
2020-01-01
Resource Type
ISSN
19326203
Other identifier(s)
2-s2.0-85078900501
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
PLoS ONE. Vol.15, No.2 (2020)
Suggested Citation
Arkom Nongnuch, Wattanachai Ngampongpan, Sirawat Srichatrapimuk, Artit Wongsa, Sutheera Thongpraphai, Chompunuch Boonarkart, Nutaporn Sanmeema, Malinee Chittaganpitch, Prasert Auewarakul, Boonrat Tassaneetrithep, Andrew Davenport, Angsana Phuphuakrat Immune response to influenza vaccination in ESRD patients undergoing hemodialysis vs. Hemodiafiltration. PLoS ONE. Vol.15, No.2 (2020). doi:10.1371/journal.pone.0227719 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/53541
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Immune response to influenza vaccination in ESRD patients undergoing hemodialysis vs. Hemodiafiltration
Abstract
© 2020 Nongnuch et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Background On-line hemodiafiltration (HDF) clears more azotemic toxins compared to high-flux hemodialysis (HD). The response to vaccination is impaired in dialysis patients. We wished to determine whether the immune responses to influenza vaccine in dialysis patients treated by HDF were stronger than those treated by HD. Materials and methods We conducted a prospective cohort study in chronic dialysis patients during the 2016 and 2017 influenza seasons. All participants received a single standard dose of trivalent influenza vaccine, and we studied the elicited humoral immune response by hemagglutination inhibition test, and cell-mediated immune response by enumeration of lymphocyte cellular markers and proliferation assays. Results We immunized 60 end-stage renal disease (ESRD) patients: 42 (70%) treated with HD and 18 patients (30%) with HDF. The median (interquartile range) age was 65.0 (55.0–74.5) years. All patients developed seroprotection to at least one influenza vaccine strain at one month post-vaccination, and did not differ between groups. By logistic regression, age was the only factor independently associated with seroconversion to all vaccine strains (odds ratio 0.89, 95% confidence interval 0.80–0.98; p = 0.022). Seroprotection to all vaccine strains was sustained for longer in patients treated with HDF, and the results remained the same after age adjustment. For cellular immune response, patients who seroconverted toall vaccine strains had higher CD38+ T cell subpopulations pre-vaccination. Patients treated by HDF had higher lymphocyte proliferation to circulating influenza A strains. Conclusions Seroconversion to all influenza vaccine strains was associated with age. Patients treated with HDF demonstrated seroprotection was sustained for longer compared to those treated by HD and greater lymphocyte proliferation to circulating influenza A strains. These encouraging results for HDF require confirmation in a larger dialysis population. Trial registration ClinicalTrial.gov, NCT04122222.